文献速递核素与放射性配体治疗肿瘤 PET/CT

不同PSMA PET入选标准对[177Lu]Lu-PSMA放射配体治疗结局的影响

Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat).
PubMed 文献 · EJNMMI Res · 2026-06-18

该回顾性研究纳入191例mCRPC患者,基于Flotufolastat PSMA PET分别按BET I期标准与VISION标准分层。161例(84.3%)同时符合两标准,17例(8.9%)仅符合VISION,13例(6.8%)均不符合,无仅符合BET者。同时符合两标准者PSA应答率与PSA-PFS最优,BET标准较VISION更严格但三组OS无显著差异。

要点

  • 84.3%患者同时符合BET与VISION标准,无仅符合BET标准者。
  • 同时符合两标准者PSA应答率39.5%,PSA-PFS 4.3个月,优于其他组。
  • BET标准更严格,主要因「多数」肿瘤体积标准排除患者。

核心结论

  • BET与VISION入选标准在[177Lu]Lu-PSMA RLT前高度重叠,多数患者同时符合两标准。
  • 同时符合两标准与最佳结局相关,BET I期标准较VISION更严格筛选患者,但三组OS无显著差异。

研究设计与样本

  • 回顾性研究,纳入机构数据库191例mCRPC患者,138例使用[18F]rhPSMA-7.3,53例使用[18F]rhPSMA-7。
  • 经 interdisciplinary board 评估适合[177Lu]Lu-PSMA RLT者,按Flotufolastat PSMA PET是否符合BET和/或VISION标准分为四组。
  • 比较PSA应答、PSA-PFS和OS,并分析BET或VISION不合格原因。

主要发现

  • 161例(84.3%)同时符合两标准(V+/B+),13例(6.8%)均不符合(V-/B-),17例(8.9%)仅符合VISION(V+/B-)。
  • BET排除的30例中17例(56.7%)缺乏「多数」肿瘤体积标准;VISION排除的13例中10例(76.9%)为内脏转移且PSMA表达低于肝脏。
  • V+/B+、V+/B-、V-/B-组PSA应答>50%分别为62/157(39.5%)、2/17(11.8%)、0/13(0%)。
  • V+/B+组PSA-PFS显著长于V+/B-和V-/B-组:4.3个月(95%CI 3.4-5.2)vs 1.5个月(95%CI 1.4-1.6)vs 2.8个月(95%CI 0.0-6.5),p=0.002。
  • OS有延长趋势但未达统计学显著:14.9 vs 13.1 vs 7.7个月,p=0.065。

关键数值与推荐

  • BET标准排除的30例中,56.7%(17/30)因缺乏「多数」肿瘤体积标准。
  • VISION标准排除的13例中,76.9%(10/13)为内脏转移且PSMA表达低于肝脏。
  • V+/B+组PSA应答>50%为39.5%(62/157),V+/B-组为11.8%(2/17),V-/B-组为0%(0/13)。

临床怎么用

  • PSMA PET入选标准可影响[177Lu]Lu-PSMA RLT患者选择与预后分层,同时符合BET与VISION标准者结局最佳。
  • BET I期标准较VISION更严格,主要因「多数」肿瘤体积标准及内脏转移PSMA表达要求。

局限性

  • 回顾性单中心研究,样本量有限,结果需前瞻性验证。
  • OS差异未达统计学显著(p=0.065),需更大样本确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [177Lu]Lu-PSMA radioligand therapy (RLT) is key in treating metastatic castration-resistant prostate cancer (mCRPC). Various PSMA agents and eligibility criteria for [177Lu]Lu-PSMA RLT have been described. We retrospectively assessed applicability and outcomes using Blue Earth Therapeutics' (BET) phase I study criteria with [18F]rhPSMA-7 and Flotufolastat ([18F]rhPSMA-7.3), comparing them to VISION trial-based PSMA PET/CT criteria. Patients eligible for [177Lu]Lu-PSMA RLT, as assessed by an interdisciplinary board, were retrospectively stratified into four groups based on whether their PSMA PET scans with Flotufolastat met BET (B + /B-) and/or VISION (V + /V-) criteria. Outcome parameters like PSA response, PSA progression-free survival (PSA-PFS), and overall survival (OS) were compared, and reasons for (in-)eligibility by BET or VISION were analyzed. RESULTS: In total, 191 mCRPC patients from our institutional database were included, of which 138 underwent [18F]rhPSMA-7.3 and 53 [18F]rhPSMA-7. 161 (84.3%) met both criteria (V + /B +), 13 (6.8%) were ineligible (V-/B-), and 17 (8.9%) met VISION but not BET criteria (V + /B-). No patient was BET-eligible without also fulfilling VISION criteria. Of the 30 patients excluded by BET criteria, 17 (56.7%) lacked the "majority" tumor volume criterion; 10/13 (76.9%) excluded by VISION had visceral metastases with lower PSMA expression than the liver. In the subgroups V + /B + , V + /B-, and V-/B-, a PSA response > 50% was present in 62/157 (39.5%), 2/17 (11.8%), and 0/13 (0%) patients, respectively. V + /B + patients had the significantly longest PSA-PFS compared to V + /B- and V-/B- (PSA-PFS: 4.3 months (95% CI 3.4 - 5.2) vs. 1.5 months (95% CI 1.4 - 1.6) vs. 2.8 months (95% CI 0.0 - 6.5), p = 0.002) and a trend towards longer OS (14.9 vs. 13.1 vs. 7.7 months, p = 0.065). CONCLUSION: Multiple similarities between BET and VISION eligibility criteria (V + /B +) prior to [177Lu]Lu-PSMA RLT were observed, with the majority of patients fulfilling both. Positivity in both criteria was associated with the best outcome. Data from our pilot cohort suggest that the criteria for BET's phase I trial select patients more strictly for [177Lu]Lu-PSMA RLT than VISION criteria, while OS did not significantly differ between the three different groups.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Grigorascu S, Langbein T, Rauscher I, et al. Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat). EJNMMI Res. 2026. PMID: 42313302. doi:10.1186/s13550-026-01459-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。